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Blastocystis anaerobic parasites are widespread worldwide in the digestive tract of many animal species,
including humans. Epidemiological Blastocystis studies are often limited by the poor sensitivity of standard
parasitological assays for its detection. This report presents a highly sensitive real-time quantitative PCR
(qPCR) assay developed to detect Blastocystis parasites in stool samples. The assay targets a partial sequence
of the Blastocystis small ribosomal subunit (SSU) rRNA gene, allowing subtyping (ST) of Blastocystis isolates
by direct sequencing of qPCR products. This qPCR method was assessed in a prospective study of 186 patients
belonging to two cohorts—a group of 94 immunocompromised patients presenting hematological malignancies
and a control group of 92 nonimmunocompromised patients. Direct-light microscopy and xenic in vitro stool
culture analysis showed only 29% and 52% sensitivity, respectively, compared to our qPCR assay. Of the 27
(14.5%) Blastocystis-positive patients, 8 (4%) experienced digestive symptoms. No correlation was found be-
tween symptomatic patients and immune status, parasite load, or parasite subtypes, although subtyping of all
isolates revealed a high (63.0%) prevalence of ST4. Two unexpected avian subtypes were found, i.e., ST6 and
ST7, which are frequently isolated in Asia but rarely present in Western countries. In conclusion, this qPCR
proved by far the most sensitive of the tested methods and allowed subtype determination by direct sequencing
of qPCR products. New diagnostic tools such as the qPCR are essential for evaluating the clinical relevance of
Blastocystis subtypes and their role in acute or chronic digestive disorders.
Blastocystis anaerobic parasites are commonly found in the
digestive tract in species of several animal groups. It is the most
prevalent protozoon found in human fecal samples and has
widespread geographic distribution (38). The role of Blastocys-
tis as a human pathogen remains unclear, but studies have
associated Blastocystis with acute or chronic digestive disorders
(19, 26). Knowledge about its life cycle is equally limited, and
various morphological forms, including the cyst and vacuolar
forms that are commonly found in feces, have previously been
described. The cyst represents the smallest (2 to 5 m in
diameter) form of the organism and is responsible for the
environmental dissemination of the parasite. The results of in
vivo experiments previously performed with mice have sug-
gested that cysts represent the infectious stage (18, 35, 37), but
the most common form detected during parasitological exam-
ination of feces is the vacuolar form (2 to 200 m in diameter)
(41, 44). The vacuolar form also represents the major parasitic
stage observed in in vitro cultures of Blastocystis parasites.
Recent molecular studies revealed high genetic diversity
among Blastocystis strains, identifying 10 different subtypes
(ST1 to ST10) that are defined by the sequence of a 600-bp
region of the gene encoding the 18S rRNA of the small ribo-
somal subunit (SSU rRNA) (20, 27, 33). Subtype distribution
differs among hosts such as mammals and birds, but recent
observations indicate that numerous subtypes previously con-
sidered “zoonotic” are also found in humans (1, 20, 38). Stud-
ies of zookeepers suggest direct transmission of Blastocystis
from animals to humans, while cyst detection in Scottish and
Malaysian sewage evidences waterborne transmission (21, 29,
37). Subtypes ST1 to ST9 have been recovered from human
fecal samples, with ST3 as the predominant ST followed by
ST1, ST2, and ST4. Subtypes ST5 to ST9 are rarely found in
human feces (29). Some subtypes have a particular distribu-
tion, such as avian subtypes ST6 and ST7, which are more
frequently found in Asia and the Middle East (38). Prevalence
levels also differ between areas and are higher in developing
countries, reaching 60% in Indonesian children (22). Blasto-
cystis species are also widely observed in developed countries,
including the United States (23%), France (3%), and the
United Kingdom (3.9%) (2, 23, 36). However, prevalence data
are largely dependent on the methods used for detection. Di-
rect-light microscopy (DLM) of fecal smears and formol-ether
concentration techniques (FECT) greatly underestimate the
prevalence of Blastocystis parasites compared to short-term
xenic in vitro cultures (XIVC) (14, 30, 36, 45). Nevertheless,
XIVC is a time-consuming diagnostic method, and some sub-
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types present a slow growth rate under culture conditions (30).
Several nonquantitative PCR (non-qPCR) assays targeting the
SSU rRNA gene to detect and discriminate between Blasto-
cystis isolates directly from stool samples have previously been
developed, and Stensvold et al. demonstrated that these mo-
lecular methods are more sensitive than XIVC (30). However,
nonquantitative PCR approaches do not establish whether
there is a correlation between parasite load and clinical
features. There is debate over the relationships between
parasite abundance and symptoms in blastocystosis. Stenzel
and Boreham associated symptomatic patients with a parasite
count of over 5 per 400 field by DLM, whereas Leder et al.
found no correlation (13, 34). However, microscopy diagnosis
frequently misses cysts, thus underestimating parasite load. In
this context, only a qPCR approach could provide clear an-
swers (14, 25, 36, 40). There has been only one recently re-
ported development of a real-time PCR assay targeting a
152-bp fragment of an unknown region of the Blastocystis ge-
nome (10). This PCR protocol was able to detect the three
major subtypes found in humans, i.e., ST1, ST3, and ST4, and
the lower limit of detection was 760 Blastocystis parasites per
100 mg of stools, but it was applied to stool samples from only
3 patients. Thus, there is a real need for highly sensitive quan-
titative tools validated for all subtypes in order to gain insights
into the physiopathology of Blastocystis infections.
Blastocystosis is generally associated with nonspecific symp-
toms such as diarrhea and/or abdominal pain (3, 13). There are
reports of acute gastroenteritis and cutaneous disorders in
some cases (8, 15), while other studies have indicated that
blastocystosis may be correlated to chronic symptoms. There is
evidence that Blastocystis species are associated with irritable
bowel syndrome (IBS) (7, 42). Numerous studies have tackled
the pathogenic ambivalence of Blastocystis. A majority of these
data focused on parasite factors in an attempt to correlate
parasite density and/or subtype with pathogenic power, with
few studies addressing host factors. A high prevalence of Blas-
tocystis in HIV patients was previously found to be associated
with clinical relevance in severely immunocompromised sub-
jects (3, 9). There are case reports of blastocystosis from other
immunocompromised patients, and one study focused on pa-
tients suffering from hematological malignancies (HM), but it
was limited to symptomatic patients (24, 39).
This paper reports development of a highly sensitive and real-
time qPCR assay targeting a region of the Blastocystis small sub-
unit rRNA (SSU rRNA) gene to detect Blastocystis parasites in
stool samples. Direct sequencing of PCR products was then
used to discriminate between subtypes. This qPCR method was
validated in a prospective epidemiological study on two co-
horts—one group of patients with hematological malignancies
and one control group of nonimmunocompromised patients.
MATERIALS AND METHODS
Clinical specimens. Stool samples from 186 patients were collected at the
Diagnostic Parasitology laboratory at the Clermont-Ferrand Hospital complex
(France), in a prospective study performed from September 2009 to April 2010.
Among the 186 patients, 94 (52 males and 42 females; mean age, 55.8  14.4
years) were hospitalized for HM. For HM patients, blood cell counts of poly-
morphonuclear neutrophils and lymphocytes were recorded on the day corre-
sponding to stool sampling. The control group, which included 92 nonimmuno-
compromised patients, had an age range (mean age, 59.4  17.4 years) and a sex
ratio (50 males and 42 females) effectively equivalent to those of the HM group.
All stool samples were analyzed within 12 h by direct-light microscopy (DLM)
and xenic in vitro culture. Aliquots of each stool were also stored at20°C before
subsequent DNA extraction for qPCR assays.
XIVC. A 500-mg aliquot of each stool sample was cultured at 37°C in Jones
medium (supplemented with 10% horse serum) in an anaerobic chamber (11).
Antibiotics (100 IU/ml penicillin and 100 g/ml streptomycin; Invitrogen,
France) were added as previously described (28). Cultures were examined using
direct-light microscopy after 72 h.
DLM. Both fecal smears and XIVC were examined using an Olympus BX
40F4 microscope under low-power (magnification of10) and high-power (mag-
nification of 40) lenses. Parasite density in fecal smears was evaluated as the
number of vacuolar forms per field (magnification, 40). Positive samples were
classified into 3 categories: under 5 parasites per field (“5”), 5 to 10 parasites
per field (“5 to 10”), and over 10 parasites per field (“10”).
Axenic in vitro culture. An axenic culture of Blastocystis subtype 7 (ST7) was
maintained in Iscove’s modified Dulbecco’s medium (IMDM) supplemented
with 10% horse serum (Invitrogen, France) and cultured in an anaerobic cham-
ber at 37°C. The strain was obtained from a stool sample from a Singapore
patient and was kindly provided by K. Tan (National University of Singapore).
DNA extraction. Total DNA from 200 mg of each stool sample was extracted
with a DNA stool minikit (Qiagen, France) and eluted in a final volume of 200
l according to the manufacturer’s recommendations. DNA extracts were stored
at 20°C until qPCR analysis.
DNA samples for qPCR controls. DNA controls representing all subtypes
found in humans were used to validate our qPCR method. DNA samples from
published isolates of ST1 (LS1 strain), ST2 (LS9 strain), ST3 (LS22 strain), and
ST4 (LS21 strain) were kindly provided by E. Viscogliosi (Institut Pasteur, Lille,
France) (28). DNA samples from rare subtypes (ST5, ST6, ST8, and ST9) were
kindly provided by C. Rune Stensvold (Statens Serum Institut, Copenhagen,
Denmark). For ST7, we used DNA extract from our axenic culture. We checked
the absence of aspecific amplification due to the main human intestinal parasites
by the use of DNA from Giardia intestinalis, Entamoeba histolytica-Entamoeba
dispar, Entamoeba coli, and Endolimax nana.
Primer design. An alignment of the SSU rRNA subtype gene sequences from
ST1 to ST10 was performed using ClustalW2 software (http://www.ebi.ac.uk
/Tools/clustalw2/index.html) to determine a target sequence for sequencing-en-
abled subtyping. A set of primers was selected in conserved regions flanking a
nonconserved region of the SSU rRNA gene for the 10 subtypes by the use of
Primer3 software (http://frodo.wi.mit.edu/primer3/). Primer pair BL18SPPF1
(5-AGTAGTCATACGCTCGTCTCAAA-3) and BL18SR2PP (5-TCTTCGT
TACCCGTTACTGC-3) amplified a DNA fragment of 320 to 342 bp, depend-
ing on the subtype. Target sequence identity among the 10 subtypes ranged from
82 to 95%.
qPCR assay. qPCR amplifications were performed using a Rotor-Gene 6000
system (Corbett Life Science, France) and a 20-l reaction volume containing 2
l of the reagent from an LC-FastStart DNA Master SYBR green kit (Roche
Diagnostics, France), 3.65 mM MgCl2, 0.5 M each primer (BL18SPPF1 and
BL18SR2PP), and 2 l of DNA extract (equivalent to 2 mg of stool). After
denaturing at 95°C for 5 min was performed, 45 cycles were run with 5 s of
denaturation at 95°C, 10 s of annealing at 68°C, and 15 s of extension at 72°C. To
establish the coefficient of correlation of the PCR assay, 10-fold dilutions of
genomic DNA (total DNA extract from a sample containing 107 Blastocystis
parasites/ml) from an axenic in vitro culture of subtype 7 (ST7) were realized.
Each dilution was run in 4 replicate experiments. For data analysis, the melting
curve and cycle threshold (CT) values were selected as the evaluation parame-
ters. The readout of the reaction with melting temperatures of 78°C to 85°C, a
dF/dT fluorescence value above 2, and a CT value below the CT of the detection
limit was used to validate a positive reaction. All clinical sample extracts were
controlled for PCR inhibitors: 1.5 l of the DNA extracts was mixed with 0.5 l
of extract from positive controls and analyzed by qPCR. Samples with a CT value
greater than the CT value of the positive control alone (2-fold diluted) were
subjected to repeat testing in a qPCR after a 10-fold dilution.
Lower limit of detection and repeatability and reproducibility assays. To
establish external standard curves for the quantification of Blastocystis and to
determine the limit of detection of our qPCR assay, we ran calibration range
analysis of Blastocystis (ST7 from the axenic in vitro culture) in Blastocystis-
negative stool samples. Ten-fold dilutions of Blastocystis consisting of 107 to 101
vacuolar forms per gram of stools were realized. Three range points (106, 104,
and 102 Blastocystis/g) were tested 8 times in the same experiment to validate
repeatability. The same samples were tested once a day for 5 days to determine
reproducibility. To analyze the reproducibility and repeatability of the qPCR
assay, both intra- and interassay coefficients of variation (CV) were assessed. CV
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values were calculated as the standard deviation “” divided by the mean “”
(CV 	 /).
Sensitivity and specificity of the qPCRs. The sensitivity and specificity of the
qPCRs were calculated for all 186 fecal samples from the clinical study and
compared to XIVC and DLM results. Sensitivity was determined as the number
of true positives divided by the sum of true positives and false negatives. Spec-
ificity was determined as the number of true negatives divided by the sum of true
negatives and false positives.
Blastocystis subtyping. Subtyping was performed by direct qPCR product se-
quencing after purification with a Nucleospin extract II kit (Macherey-Nagel,
France). Sequencing was performed by Eurofins MWG Operon (Germany)
using the same primers as those used for PCR (BL18SPPF1 and BL18SR2PP).
Sequences were analyzed using the Basic Local Alignment Search Tool (BLAST;
http://blast.ncbi.nlm.nih.gov/). Subtypes were assigned according to the recent
classification method by Stensvold et al. for a query coverage  98% with exact
match or identity  98% (30).
Other pathogens. Other parasites were detected by direct-light microscopy of
fecal smears, and stool samples were concentrated using merthiolate iodine
formaldehyde (MIF) and Parasitochrome Plus (Bailenger method; Biomedical
diagnostics, France). Positive stool samples from symptomatic patients were
screened to detect viral and bacterial pathogens. Major viruses responsible for
gastroenteritidis were screened, including Norovirus strains (by using the Rida
Quick Norovirus test [R-Biopharm, France]) and Rotavirus and Adenovirus
strains (by using the Rida Quick Rotavirus/Adenovirus Combi test [R-Biopharm,
France]). Conventional bacteriological media were used to detect Salmonella,
Shigella, Campylobacter, and Clostridium difficile species.
Statistical analysis. Except for the variables needing a two-tailed Fischer exact
test, the data were analyzed using Epi-Info version 6.02 software and the 
2 test.
RESULTS
Real-time qPCR development. A qPCR assay targeting a
region of the Blastocystis SSU rRNA gene was developed to
detect and quantify subtypes ST1 to ST10 directly from human
stool specimens. The amplified DNA fragments were 320 to
342 bp in size, depending on subtype (Fig. 1). As shown in Fig.
2A, DNAs from the 9 subtypes (ST1 to ST9) found in human
feces were successfully amplified, with melting temperatures
between 78°C and 85°C, depending on subtype. The criteria
used to define a positive reaction were a melting temperature
of 78°C to 85°C and a dF/dT fluorescence value above 2 (Fig.
2B and C). A good negative regression was observed in com-
parisons of 10-fold dilutions of Blastocystis ST7 DNA extract
and CT values (R
2 	 0.99). PCR efficiency was 0.87. With an
extraction range of live parasites in stool samples from 107 to
10 Blastocystis parasites/g, it was possible to detect as few as 102
Blastocystis parasites/g of stools. The standard curve from the
extraction range was then used to quantify parasite load in the
stool samples.
Both intra- and interassay CV values were assessed to ana-
lyze the reproducibility and repeatability of the qPCR assay.
Eight replicates of 106, 104, and 102 Blastocystis/g were ana-
lyzed in a single run. The CT intra-assay CV values for the
replicate experiments were 0.47%, 0.55%, and 0.47% for the
106, 104, and 102 concentrations, respectively. In addition, 5
runs of the 3 concentrations were performed at different days.
The CT interassay CV values for the range points 10
6, 104, and
102 Blastocystis/g were 0.82%, 0.50%, and 1.06%, respectively.
Prospective study with two patient cohorts. Stool samples
from 186 patients were collected in a prospective study per-
formed from September 2009 to April 2010. Among the 186
patients, 94 presented hematological malignancies (HM) and
92 were nonimmunocompromised (control group). The qPCR
assay gave an overall prevalence of 27 (14.5%) Blastocystis-
positive patients among the 186. The mean of the ages of
Blastocystis-positive patients was 57.2 16.4 years (57.7 16.0
years in Blastocystis-negative patients), with a female-to-male
gender ratio of 1.45 (0.82 in Blastocystis-negative patients). The
prevalence values for the 2 cohorts were 16% (15 of 94) in the
HM group and 13% (12 of 92) in the control group. For each
Blastocystis-positive sample, parasite density was quantified us-
ing qPCR. Parasite counts ranged from 102 to 107 Blasto-
cystis/g of stool sample (Table 1). Among the 27 Blastocystis-
positive patients, two were coinfected by Giardia intestinalis. Of
the 25 patients infected only with Blastocystis parasites, 8 (4
from the HM group and 4 controls) experienced overt symp-
toms. Bacteriology and virology assay results were negative for
these 8 patients, 7 of whom had diarrhea episodes of liquid
(n 	 3), soft (n 	 1), mucous (n 	 1), or normal (n 	 2) stools
on the day of sampling. One patient had normal stools asso-
ciated with constipation. Of the three Blastocystis-positive pa-
tients with diarrhea, one had weight loss, two had abdominal
pain, and one also had anorexia. Three Blastocystis-positive
patients were on antibiotherapy. No correlation was found
between parasite count and clinical expression of symptoms.
All the PCR-positive samples were then sequenced to discrim-
inate between subtypes and determine subtype prevalences in
both the HM and control groups (Table 2). Among the 27
Blastocystis-positive samples, 15 were from the HM group and
12 were from the control group. Six different subtypes (ST1, -2,
-3, -4, -6, and -7) were determined by direct sequencing of
qPCR products. ST3, ST4, and ST7 were identified in both
groups, with ST4 being the most predominant (17/27), fol-
lowed by ST3 (4/27) and ST7 (3/27). In contrast, ST6 was found
only in the HM group (1/15), while ST1 and ST2 were found
only in the nonimmunocompromised group (1/12 for both).
Considering symptomatic patients with no other pathogens
identified (8/27; Table 2), ST4 still proved the most dominant
(5/8), followed by ST3 (2/8) and ST7 (1/8).
Comparison of real-time qPCR with microscopy and culture
methods. We compared our qPCR assay with conventional
diagnostic methods, including direct-light microscopy (DLM)
and xenic in vitro culture (XIVC) of fresh stool samples. Only
8 Blastocystis-positive samples were detected by DLM and
14 by XIVC (Table 1), whereas the qPCR assay detected 27
Blastocystis-positive samples (confirmed by sequencing of am-
plified products), making it by far the most sensitive method.
The qPCR assay was then used as the “gold standard” to
calculate the sensitivity of both XIVC (52%) and DLM (29%).
The limit of detection of qPCR was established as 102 Blasto-
cystis parasites/g of stools, but we were unable to determine the
limit of detection for XIVC. Indeed, XIVC did not detect
any stool containing less than 4.85  104 Blastocystis para-
sites/g of stools, but it also failed to return a positive result
for four samples containing more parasites than this thresh-
old, i.e., one containing 7.51  105 Blastocystis parasites/g of
stools, one containing 5.79  106 Blastocystis parasites/g,
and two others containing 107Blastocystis parasites/g as de-
termined by qPCR (patients 28, T85, and 44 and 80, respec-
tively; see Table 1). We identified 8 false-positive samples
using our qPCR by sequencing the PCR product (specificity 	
95.0%), whereas the specificities of both the DLM diagnostic
method and the XIVC diagnostic method were 100%.
Cross-comparison between diagnostic methods revealed the
impact of each method on subtype distribution. Indeed, the
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prevalence of ST4 was 38% by the DLM method, rising to
50% with XVIC and 63% with our qPCR diagnostic method
(Fig. 3).
DISCUSSION
Highly sensitive tools are needed to study the epidemiolog-
ical features of blastocystosis. Until now, short-term xenic in
vitro culture (XIVC) has been widely considered the gold stan-
dard method. Several studies have shown that XIVC is more
efficient than DLM or formol-ether concentration (FECT) in
detection of Blastocystis parasites in stool samples (14, 40, 45).
Our study confirmed the poor (57%) sensitivity of DLM com-
pared to XIV (previously reported by Leelayoova et al. and
Termmathurapoj et al.; 14, 40). The superiority of XIVC is
likely due to multiplication of the parasites in culture and to
the detection of small forms such as cysts after excystation.
Cysts are common in stools, with a prevalence rate of up to
28.5% in stool samples from Blastocystis-positive patients, but
escape diagnosis due to their small size, resulting in significant
underestimation of prevalence (14, 25, 36, 40). In our study,
the overall prevalence according to DLM was only 4%, a result
similar to the 3% found by Pinel et al. in a study performed
with 2,581 patients in another region of France in 1999 (23).
FIG. 1. (A) Localization of the target sequence in the SSU rRNA gene for subtype 7. (B) ClustalW alignment of the target sequence (SSU
rRNA) from subtype ST1 to ST10. Primers (BL18SPPF1 and BL18SPPR2) are indicated in bold and underlined. The target sequence length ranges
from 320 to 342 bp, and sequence identity among the 10 subtypes ranges from 82% to 95%.
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However, the prevalence reported by Pinel et al. was probably
greatly underestimated, since a prevalence of 14.5% was ob-
tained with our qPCR assay.
qPCR can detect all forms of Blastocystis parasites, including
cysts, and allows quantification of the parasite. We confirmed
that the poor sensitivity of DLM could be explained by the lack
of detection of cysts, as was the case with patient 34 (see Table
1), who was found to harbor107 Blastocystis/g of stool sample
by qPCR whereas the corresponding DLM result was negative.
XIVC was also able to detect cysts; however, compared to our
qPCR, its sensitivity was only 52% and it failed to give a
positive result for 3 samples containing more than 106 Blasto-
cystis/g of stool. Stensvold et al. (30) compared their PCR assay
to XIVC and concluded that the sensitivity of XIVC was 89%.
They suggested that some fecal samples did not contain viable
Blastocystis or that cultured organisms were so inconspicuous
that the XIVC analysis missed them (30). We also demon-
strated that our qPCR assay was more sensitive than XIVC:
among the 13 qPCR-positive/XIVC-negative samples, 8 con-
tained fewer than 103 Blastocystis/g of stool sample, which was
near the lower limit of detection of our qPCR assay (102
Blastocystis/g). The overall prevalence in our study was 14.5%,
but only one stool sample was tested per patient. The diagnos-
tic procedure could probably be made more sensitive by se-
FIG. 2. (A) Subtype DNA samples from ST1 to ST9 were subjected to the qPCR assay. Melting peaks for these subtypes were between 78°C
and 84°C. (B and C) Readouts of the reaction with a melting temperature of 78°C to 84°C, dF/dT fluorescence above 2, and CT value below the
CT of the limit of detection were used to indicate a positive result.
VOL. 49, 2011 A qPCR ASSAY TO DETECT BLASTOCYSTIS IN HUMAN STOOLS 979
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quential analysis of 2 to 3 stool samples, as is routinely done by
laboratories running standard parasitological assays. Multiple
assays could also be valuable for optimizing the quantification
of parasite burden for each patient. To improve the sensitivity
of qPCR, it is also necessary to control the absence of PCR
inhibitors. Indeed, inhibitors were detected in 16 samples, and
1 of them gave a positive result after 10-fold dilution of the
corresponding DNA extract. One study developed a qPCR
assay in which the limit of detection was down to 760 Blasto-
cystis per 100 mg of stool sample, detecting a 152-bp fragment
from an unknown region (10). That assay, which was tested
with ATCC strains (including ST1, ST3, and ST4 strains) and
applied to stool samples from 3 patients, highlighted the dif-
ficulty of developing a qPCR assay that allows detection of all
Blastocystis subtypes due to the broad genetic variability in-
volved. Our qPCR assay was designed to allow detection of the
10 subtypes of Blastocystis, and we checked its ability to detect
Blastocystis from DNA extracts of typed isolates of the 9 sub-
types (ST1 to ST9; see Fig. 2A) already found in human stools
(38). As stated above, the specificity of our SYBR green-based
qPCR assay was 95%. Specificity would be enhanced by using
probe-based qPCR assays. However, the only sequence avail-
able for all the subtypes was the SSU rRNA sequence, and the
extensive genetic variability made it impossible for us to design
probe-based qPCR assays. We chose to use this high variability
to set up primers amplifying a variable region of the SSU
rRNA gene among the 10 subtypes, thus allowing subtyping by
direct sequencing of qPCR products.
Interestingly, sequencing of Blastocystis-positive samples re-
vealed that ST4 was the most prevalent subtype (63.0%), fol-
lowed by ST3 (14.8%) and ST7 (11.1%) and then ST1, ST2,
and ST6 (3.7% each). ST3 is usually the major subtype found
in humans, whereas ST4 is a minor subtype found in rodents
(38). Only one study in Spain reported a very high prevalence
of ST4 associated with symptomatic patients (4). Although the
lack of a significant association of subtype with disease may
have been due to the small number of Blastocystis-positive
patients in our study, we observed that patients carrying ST4
were no more subject to symptomatic infections than those
carrying another ST. The significance of the high prevalence of
ST4 remains unclear, and there is a need for molecular studies
to be performed on potential reservoirs in the same area. We
identified 3 patients carrying ST7 and one carrying ST6, which
was an unexpected finding, given that these avian STs are
rarely found in Western countries (38). Our results differ sig-
nificantly from recently published French data reporting ST3
(53.5%) as the most prevalent ST, followed by ST1 (25.6%),
ST4 and ST2 (9.3%), and ST7 (2.3%) (28). These differences
could be due to the methodology used to isolate Blastocystis, as
shown in Fig. 3. Indeed, the distribution of subtypes was de-
pendent on the diagnostic method used, as DLM and XVIC
failed to detect a large fraction of ST4 carriers that were
detected by qPCR. Our report is the first to clearly demon-
strate the impact of detection methods on relative distributions
of subtypes. It can also be hypothesized that ST distribution
differs between areas depending on reservoirs and modes of
contamination, and even in the same country, as shown on a
large scale in China (16). Data published by Souppart et al.
(28) came from patients hospitalized in Lille, a big city in
northern France, whereas animal reservoirs and food habits
may differ significantly between the two areas studied, with
Clermont-Ferrand hospitals probably receiving more “rural
area” patients than Lille hospitals. Finally, subtyping by direct
sequencing of qPCR products did not allow detection of mixed
infections by several STs known to occur only in 2.6% to 14.6%
of positive samples (17, 43). The results of recent work in
mouse studies suggest that Blastocystis species are able to in-
filtrate the digestive epithelium, invading the muscle layer (5).
Nevertheless, the pathogenic potential of Blastocystis remains
unclear, and relationships between symptoms and parasite
density and/or subtype have never been unambiguously dem-
onstrated. Stenzel and Boreham correlated symptomatic pa-
tients with a parasite count higher than 5 per 400 field by
DLM, whereas Leder et al. did not find any correlation (13,
34). We did not find any correlation between parasite load
determined by qPCR (ranging from 102 to 107 Blastocystis
parasites/g of stools from symptomatic patients) and symp-
toms. This suggests that parasite shedding in stools does not
reflect interactions with the host in the digestive tract. Also,
FIG. 3. Distribution of the Blastocystis subtypes from our prospec-
tive study according to diagnostic method used. Eight samples tested
positive with DLM versus 14 with XIVC and 27 with qPCR. The
prevalence of subtype 4 determined with DLM was just 38%, increas-
ing to 50% with XVIC and to 63% with qPCR.
TABLE 2. Subtype distribution of Blastocystis isolates collected
from both the immunocompromised hematological malignancy
group and nonimmunocompromised control group patients
as determined using the qPCR assay
Group
% of isolates of indicated subtype (no. of isolates)
ST1 ST2 ST3 ST4 ST6 ST7
HMa 20.0 (3) 66.7 (10) 6.7 (1) 6.7 (1)
Control 8.3 (1) 8.3 (1) 8.3 (1) 58.3 (7) 16.7 (2)
Total 3.7 (1) 3.7 (1) 14.8 (4) 63.0 (17) 3.7 (1) 11.1 (3)
a HM, hematological malignancy.
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qPCR was able to quantify both cyst and vacuolar forms, and
it is possible that the vacuolar form gives a better reflection of
pathogenicity, as suggested by Elwakil and Hewedi (5).
In our study, Giardia intestinalis was the only other pathogen
found to be associated with Blastocystis parasites. We found no
patients positive for Dientamoeba fragilis, which is frequently
associated with Blastocystis infections (32). This may be due to
poor sensitivity of standard parasitological assays (31). Eight
symptomatic patients—4 from the control group (nonimmu-
nocompromised) and 4 from the immunocompromised group
presenting hematological malignancies (HM) group–were shown
to be infected by only Blastocystis parasites. Among those 8
symptomatic patients, 5 were subtyped as harboring ST4, 2 as
harboring ST3, and 1 as harboring ST7. Our study was initially
designed to integrate host factors by comparing HM patients
to controls. The few clinical data available on Blastocystis in-
fections in immunocompromised patients essentially concern
HIV patients. An Ethiopian study found a higher prevalence of
Blastocystis parasites in a HIV cohort (9), while Kurniawan et
al. (12) studied 318 HIV patients before antiretroviral therapy
was administered and found that Blastocystis species were
more prevalent when the lymphocyte CD4 count was below 200
CD4/mm
3, and Cirioni et al. associated the presence of Blas-
tocystis with symptoms at a CD4 count of 200 CD4/mm
3 (3).
Other categories of immunocompromised patients, such as
renal transplant recipients, can develop blastocystosis (24).
HM patients are at risk for opportunistic infections, especially
before and in the weeks following stem cell transplantation.
Gosh et al. reported a case of exacerbated intestinal symptoms
in a patient with digestive graft versus host disease (6). Tas¸ova
et al. studied the prevalence of Blastocystis in HM patients
with gastrointestinal complaints (GC) compared to the prev-
alence in a group of nonimmunocompromised patients with
GC (39). In contrast with our data, Blastocystis species were
more frequently involved in GC in patients from the HM
group than in the nonimmunocompromised symptomatic pa-
tients. In our study, we also looked at the white cell blood
count in the HM patients with positive qPCR results for Blas-
tocystis parasites. Three of the 4 symptomatic HM patients had
lymphopenia, and two had neutropenia. However, other pa-
tients from the HM group with positive test results had the
same hematological abnormalities without gastrointestinal
symptoms (see Table 2).
In summary, we developed a highly sensitive qPCR assay
enabling the detection and quantification of Blastocystis iso-
lates directly from human stool samples. Using this qPCR
method, we detected 2-fold-more positive patients than with
the culture approach that to date has been accepted as the gold
standard method. The qPCR assay can be easily applied to
large epidemiological studies, with rapid results compared to
xenic cultures. The molecular method was validated through
a prospective epidemiological study of 2 cohorts—one
group consisting of patients presenting hematological malig-
nancies and one control group of nonimmunocompromised
patients. Host factors and intrinsic parasite factors such as
parasite density and/or subtype were not correlated with
pathogenicity. Further studies are now required on larger pa-
tient populations. All Blastocystis-positive samples were easily
subtyped by direct sequencing of qPCR products, revealing an
unexpected subtype distribution with a high prevalence of sub-
type 4. This study demonstrated the impact of detection meth-
ods on relative subtype distributions, thus underlining the need
to harmonize the diagnostic tools used for epidemiological
studies.
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